Qualitative or quantitative defects of glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase -

Qualitative or quantitative defects of glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE) refer to disorders caused by mutations in the GNE gene, which encodes a bifunctional enzyme critical for the biosynthesis of sialic acid (N-acetylneuraminic acid). Sialic acid is an essential sugar molecule that modifies proteins and lipids on cell surfaces throughout the body, playing important roles in cell signaling, structural integrity, and immune function. Defects in GNE can lead to several distinct clinical conditions, most notably GNE myopathy (also known as hereditary inclusion body myopathy type 2, Nonaka myopathy, or distal myopathy with rimmed vacuoles) and sialuria. GNE myopathy is characterized by progressive muscle weakness typically beginning in early adulthood, initially affecting the distal muscles of the lower limbs (particularly the tibialis anterior), with gradual proximal spread. The quadriceps muscles are characteristically spared until late in the disease course, which is a hallmark diagnostic feature. Sialuria, caused by gain-of-function mutations in the allosteric feedback domain of GNE, presents differently with coarse facial features, hepatomegaly, and developmental delay. The primary body systems affected depend on the specific type of GNE defect. In GNE myopathy, the skeletal muscular system is predominantly involved, leading to progressive disability and eventual loss of ambulation typically within 10-20 years of symptom onset. Muscle biopsy characteristically shows rimmed vacuoles and cytoplasmic inclusions. In sialuria, multiple organ systems may be affected. Diagnosis is confirmed through genetic testing of the GNE gene and, in some cases, measurement of sialic acid levels. Currently, there is no approved curative treatment for GNE-related disorders. Management is primarily supportive, including physical therapy, assistive devices, and monitoring for respiratory complications. Investigational therapies, including sialic acid supplementation (such as aceneuramic acid/ManNAc), have been explored in clinical trials for GNE myopathy, though results have been mixed. Gene therapy approaches are also under investigation.

Common questions about Qualitative or quantitative defects of glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase -